May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Ocular Effects of Nepafenac Ophthalmic Suspension Following Six Months of Topical Ocular Administration to Pigmented Rabbits
Author Affiliations & Notes
  • J. Heaton
    Toxicology, Alcon Research, Ltd., Fort Worth, TX
  • J.W. Hiddemen
    Toxicology, Alcon Research, Ltd., Fort Worth, TX
  • R.B. Hackett
    Toxicology, Alcon Research, Ltd., Fort Worth, TX
  • R.L. Rice
    Toxicology, Alcon Research, Ltd., Fort Worth, TX
  • M.M. Gruebbel
    Experimental Pathology Laboratories, Inc., Durham, NC
  • Footnotes
    Commercial Relationships  J. Heaton, Alcon Research, Ltd E; J.W. Hiddemen, Alcon Research, Ltd. E; R.B. Hackett, Alcon Research, Ltd. E; R.L. Rice, Alcon Research, Ltd. E; M.M. Gruebbel, None.
  • Footnotes
    Support  Alcon Research, Ltd
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2650. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Heaton, J.W. Hiddemen, R.B. Hackett, R.L. Rice, M.M. Gruebbel; Ocular Effects of Nepafenac Ophthalmic Suspension Following Six Months of Topical Ocular Administration to Pigmented Rabbits . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2650.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To determine the ocular irritation and systemic toxicity potential of nepafenac ophthalmic suspensions when dosed 3 times/day to pigmented rabbits for 6 months. Methods: Five groups of 14 animals received 2 drops of 0 (vehicle), 0.3, 1 or 1.5% Nepafenac Ophthalmic Suspension in the right eye 3 times daily for 6 months. An additional group of rabbits was maintained as an Untreated Control group. Clinical signs, body weights, ocular findings and clinical pathology were assessed during the study. At completion of the study, ocular tissues and major organs were submitted for histopathological examination. Results: No adverse treatment–related clinical signs or body weight changes were observed. Biomicroscopy revealed no significant treatment–related findings. Indirect ophthalmoscopic evaluations determined that all animals remained within normal limits during the study. Statistical analyses of the pachymetry, intraocular pressure, specular microscopy, clinical pathology and organ weight measurements revealed no findings attributed to topical ocular treatment with nepafenac suspensions. Microscopic evaluation of the ocular tissues and major organs revealed no evidence of ocular or systemic toxicity. Conclusions: Over a 6 month period, daily topical ocular application of 0.3% to 1.5% suspensions of nepafenac produced no significant ocular findings and no ocular or systemic toxicity.

Keywords: cornea: basic science • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×